Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetazolamide + platinum + etoposide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves **acetazolamide**, a carbonic anhydrase inhibitor; **platinum** compounds, which are DNA alkylating agents; and **etoposide**, a topoisomerase II inhibitor. The combination is being studied for its potential in treating various cancers, including small cell lung cancer, by enhancing the effects of chemotherapy and radiotherapy.
02
Targets
CA (Carbonic anhydrase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on acetazolamide + platinum + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetazolamide + platinum + etoposide.